Among patients with NSCLC, MET amplification and MET protein overexpression were associated with ORRs of 24.5% (95% CI, 0.187–0.322) and 21.8% (95% CI, 0.150–0.317) without heterogeneity, respectively. This evidence concerns the gene MET and non-small cell lung carcinoma.